Copyright
©The Author(s) 2022.
World J Transplant. Nov 18, 2022; 12(11): 331-346
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.331
Published online Nov 18, 2022. doi: 10.5500/wjt.v12.i11.331
Table 1 Clinical trials assessing the effectiveness of immunotherapy in patients with advanced hepatocellular carcinoma
Trial name | Phase | Intervention | Status |
Single-agent immunotherapy | |||
NCT02576509 | III | Nivolumab vs sorafenib | Completed |
NCT02702414 | II | Pembrolizumab (single-arm study) | Completed |
NCT02702401 | III | Pembrolizumab vs BSC | Completed |
NCT03062358 | III | Pembrolizumab and BSC vs BSC and placebo | Not yet completed; estimated completion date: June 2023 |
NCT03412773 | III | Tislelizumab vs sorafenib | Not yet completed; estimated completion date: May 2022 |
NCT02989922 | II/III | Camrelizumab (single-arm study) | Not yet completed |
NCT01008358 | II | Tremelimumab (single-arm study) | Completed |
Combination of immunotherapy with other treatment modalities1 | |||
NCT02423343 | I/II | Galunisertib and nivolumab (dose escalation and cohort expansion study) | Completed |
NCT03893695 | I/II | Ascrinvacumab and nivolumab (single-arm study) | Not yet completed; estimated completion date: June 2022 |
NCT03059147 | I | PI3 kinase/BRD4 inhibitor small molecule and nivolumab (single-arm study) | Not yet completed; estimated completion date: October 2022 |
NCT03211416 | I/II | Pembrolizumab and sorafenib | Not yet completed; estimated completion date: December 2022 |
NCT03713593 | III | Lenvatinib and pembrolizumab vs Lenvatinib and placebo | Not yet completed; estimated completion date: December 2023 |
NCT03316872 | II | Pembrolizumab and SBRT (single-arm study) | Not yet completed; estimated completion date: December 2023 |
NCT03099564 | I | Pembrolizumab and Radioembolization (single-arm study) | Not yet completed; estimated completion date: June 2022 |
NCT03939975 | II | Pembrolizumab or nivolumab or toripalimab with thermal ablation, RFA or MWA | Completed |
NCT02715531 | I | Atezolizumab with bevacizumab or other chemotherapy agents | Completed |
NCT03434379 | III | Atezolizumab and bevacizumab vs Sorafenib | Not yet completed; estimated completion date: June 2022 |
NCT03755791 | III | Atezolizumab and cabozantinib vs sorafenib vs cabozantinib | Not yet completed; estimated completion date: December 2023 |
NCT04310709 | II | Reforafenib and Nivolumab (single-arm study) | Not yet completed; estimated completion date: May 2023 |
NCT03869034 | II | HAIC and sintilimab vs HAIC | Completed |
NCT03794440 | II/III | Anti-VEGF monoclonal antibody and sintilimab vs sorafenib | Not yet completed; estimated completion date: December 2022 |
NCT03764293 | III | Apatinib and PD1 monoclonal antibody vs sorafenib | Not yet completed; estimated completion date: June 2022 |
NCT03755739 | II/III | Pembrolizumab and/or ipilimumab administered via arterial infusion or intra-tumor fine needle injection vs pembrolizumab and/or ipilimumab administered via vein infusion | Not yet completed; estimated completion date: November 2033 |
NCT04273100 | II | PD1 monoclonal antibody and TACE and lenvatinib (single-arm study) | Not yet completed |
NCT03857815 | II | PD1 monoclonal antibody and SBRT (single-arm study) | Not yet completed |
NCT01853618 | I/II | Tremelimumab and/or TACE and/or RFA (sequential assignment) | Completed |
NCT04124991 | I/II | Durvalumab and TARE (single-arm study) | Not yet completed |
NCT03475953 | I/II | Regorafenib and avelumab (sequential assignment) | Not yet completed; estimated completion date: December 2022 |
- Citation: Ouranos K, Chatziioannou A, Goulis I, Sinakos E. Role of immunotherapy in downsizing hepatocellular carcinoma prior to liver transplantation. World J Transplant 2022; 12(11): 331-346
- URL: https://www.wjgnet.com/2220-3230/full/v12/i11/331.htm
- DOI: https://dx.doi.org/10.5500/wjt.v12.i11.331